The Duration Study
An Open Label Randomized Study To Evaluate The Response Rate Of Epoetin Alfa (PROCRIT�) Versus No/Delayed PROCRIT Treatment In Patients With Cancer And Persistent Chemotherapy-Induced Myelosuppression (Anemia)
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Terminated
This study was stopped early due to slow enrollment.
Other terminated trials from Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Follicular Lymphoma · Phase PHASE2 · Oct 2011
- Advanced or Refractory Leukemia · Phase PHASE1 · Sep 2011
- Mononeuropathies · Phase PHASE2 · Jul 2011
- Arthralgia · Phase PHASE2 · Jul 2011
- Interstitial Cystitis · Phase PHASE4 · Jun 2011
More terminations from Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Other Anemia trials with similar outcome
A PHASE3 clinical study on Anemia, this trial is terminated or withdrawn. The trial is conducted by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. and has accumulated 5 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE3
First recorded
Jun 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Ortho Biotech Products, L.P.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.